Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
465 results about "Glioblastoma" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A cancerous tumor which develops in the brain.
Use of CDK inhibitor for the treatment of glioma
ActiveUS8946226B2Prevent proliferationReduce molecular weightOrganic active ingredientsOrganic chemistryGlioblastomaCytotoxicity
Owner:NERVIANO MEDICAL SERVICES SRL
Therapeutic uses of tim-3 modulators
InactiveUS20100061992A1Increase TIM- activityIncrease secretionSenses disorderNervous disorderDiseaseGlioblastoma
The invention provides novel methods of treating neurological disorders, including neurodegenerative disorders such as MS. The invention also provides novel methods of treating cancers, including glial tumors such as glioblastoma multiforme. The invention further provides vaccines and related uses.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
InactiveUS6127415APreventing and controlling photoinducedPreventing and controlling and chronologic agingBiocideCosmetic preparationsDiseaseAnticarcinogen
PCT No. PCT / US97 / 11564 Sec. 371 Date Apr. 14, 1999 Sec. 102(e) Date Apr. 14, 1999 PCT Filed Jul. 8, 1997 PCT Pub. No. WO98 / 01132 PCT Pub. Date Jan. 15, 1998The present invention relates to specific adamantyl or adamantyl group derivative containing retinoid compounds induce apoptosis of cancer cells. These adamantyl retinoid derivatives are useful for the treatment of many cancers and solid tumors, especially androgen-independent prostate cancer, skin cancer, pancreatic carcinomas, colon cancer, melanoma, ovarian cancer, liver cancer, small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, brain cancer, bladder cancer, breast cancer, neuroblastoma / glioblastoma, and leukemia. Also, the invention relates to novel adamantyl or adamantyl group derivative compounds which are useful as active agents for the treatment or prevention of keratinization disorders and other dermatological conditions, and other diseases.
Owner:GALDERMA RES & DEV SNC
Anti-cancer antibodies with reduced complement fixation
ActiveUS20050202021A1Reduce complement fixationReduce pain levelsPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAbnormal tissue growthBlastoma
The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
Owner:MERCK PATENT GMBH
System and method for the treatment of cancer, including cancers of the central nervous system
The invention relates to the treatment of cancer, and particularly to the treatment of cancers of the central nervous system, such as glioblastoma multiforme. A dual therapeutic approach is provided, including the administration of a dendritic cell-based cancer vaccine and a regimen of chemotherapy. The two therapies may be administered concurrently with one another and / or with an initial vaccination preceding chemotherapy. In various embodiments, the dendritic cell-based cancer vaccine includes either primed or unprimed dendritic cells; for instance, the dendritic cells may be autologous tumor antigen-presented dendritic cells. The dual therapeutic approach of the instant invention beneficially influences the chemosensitivity of a mammal with cancer.
Owner:CEDARS SINAI MEDICAL CENT
Using Alternating Electric Fields to Increase Cell Membrane Permeability
ActiveUS20200009377A1Good cell membrane permeabilityReduced viabilityElectrotherapyEnergy modified materialsCancer cellCell membrane
Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).
Owner:NOVOCURE GMBH +1
Compositions and Methods for Treating Glioblastoma GBM
Methods of treating a malignant glioma in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a viral vector comprising: (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), said first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter.
Owner:VASCULAR BIOGENICS
Anti-tumoural effects of cannabinoid combinations
ActiveUS8632825B2Prevent induced cellBiocideHydroxy compound active ingredientsGlioblastomaCannabinoid
The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumor, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).
Owner:GW PHARMA LTD
Methods and compositions for treating cancer
Methods and compositions provided herein relate to the treatment of cancer. In some embodiments, the compositions have utility in the treatment of cancers including glioblastoma multiforme and lung cancer.
Owner:GEORGETOWN UNIV
Methods and compositions for treating cancer
Methods and compositions provided herein relate to the treatment of cancer. In some embodiments, the compositions have utility in the treatment of cancers including glioblastoma multiforme and lung cancer.
Owner:GEORGETOWN UNIV
Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents)
The invention relates to the use of one or more cannabinoids, particularly THC and / or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). The non-cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.
Owner:GW PHARMA LTD
N-acyl ureas exhibiting anti-cancer and anti-proliferative activities
Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.
Owner:DECIPHERA PHARMA LLC
Anti-cancer activity of carvedilol and its isomers
InactiveUS6632832B1Inhibits COX activityPrevent and inhibit tumor growthBiocideArtificial cell constructsMelanomaProstate cancer
The present invention provides for pharmaceutical compositions comprising carvedilol for treatment of cancer. More particularly the invention relates to the use of carvedilol for treatment of cancers of the colon, ovary, breast, prostate, pancreas, lung, melanoma, glioblastoma, oral cancer and leukemias. Although not bound to any theory, the anticancer activity of carvedilol appears to be attributed to the inhibition of Epidermal Growth Factor and Platelet derived growth factor dependent proliferation of cancer cells. Further, carvedilol exerts anticancer effect by inhibition of the Protein kinase C (PKC) activity and that of the cyclooxygenase 2 enzyme. The invention also relates to the anticancer activity of the optically pure isomers S(-) and R(+) of carvedilol and the use of carvedilol and its isomers in pharmaceutical compositions for the treatment of cancer.< / PTEXT>
Owner:DABUR RESEARCH FOUNDATION
Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class i or class ii molecules for vaccine
ActiveUS20100158929A1Good adjuvant effectIncrease heightPeptide/protein ingredientsMetabolism disorderKidney cancerGlioblastoma
The present invention relates to novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules as vaccines for the use in immunotherapeutic methods. In particular, the present invention relates to formulations for the immunotherapy of cancer, in particular renal and brain cancer, in particular glioma, especially glioblastoma cancer. The present invention furthermore relates to vaccine compositions for eliciting anti-tumour immune responses.
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Using Alternating Electric Fields to Increase Cell Membrane Permeability
PendingUS20200009376A1Good cell membrane permeabilityReduced viabilityElectrotherapyEnergy modified materialsCancer cellGlioblastoma
Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
Use of phosphatases to treat tumors overexpressing N-CoR
InactiveUS20090018142A9Great likelihoodSuccessful treatmentOrganic active ingredientsMicrobiological testing/measurementAbnormal tissue growthRetinoid receptor
Owner:UNITED STATES OF AMERICA +1
Method of diagnosing and treating gliomas
InactiveUS6870029B2Reduce current amplitudeSmall sizePeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsGlioblastomaMonoclonal antibody
The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.
Owner:UAB RES FOUND
Combination therapy for the treatment of glioblastoma
ActiveUS20150065781A1Extension of timeOrganic active ingredientsImmunoglobulins against growth factorsGlioblastomaCombined Modality Therapy
This invention concerns methods of treating a patient diagnosed with glioblastoma comprising administering to said patient a therapy comprising an effective amount of an anti-VEGF antibody and a chemotherapeutic.
Owner:GENENTECH INC
Identification method of primary central nervous system lymphoma and glioblastoma based on sparse representation system
ActiveCN107016395AEliminate redundancyReduce computationImage enhancementImage analysisDictionary learningGlioblastoma
The invention belongs to the technical field of computer auxiliary diagnosis, and specifically relates to an identification method of primary central nervous system lymphoma and glioblastoma based on a sparse representation system. The method includes: segmenting T1 enhanced and T2 weighted MRI image tumor regions by employing an image segmentation method based on a convolutional neural network; then designing a dictionary learning and sparse representation method, and extracting texture characteristics of the tumor regions; selecting some characteristics with high stability and high resolution for tumor identification by employing an iterative sparse representation characteristic selection method in order to reduce the characteristic redundancy and improve the tumor identification efficiency; and finally establishing a combined sparse representation classification model containing two modals of T1 enhanced or T2 weighted based on the thought of eigenstate fusion in order to improve the tumor identification precision. According to the method, high tumor identification precision can be obtained, manual operation for extraction of identification parameters is avoided, the robustness is high, and the method can be applied to clinic identification of primary central nervous system lymphoma and glioblastoma.
Owner:FUDAN UNIV
Recombinant poliovirus for the treatment of cancer
The present invention is directed to non-pathogenic, oncolytic, recombinant polioviruses for the treatment of various forms of malignant tumors. The recombinant polioviruses of the invention are those in which the internal ribosomal entry site (IRES) of the wild type poliovirus was exchanged with the IRES of other picornaviruses, and optionally P1, P3 or the 3'NTR thereof was exchanged with that of poliovirus Sabin type. More particularly, the present invention is directed to the administration of the non-pathogenic, oncolytic, recombinant poliovirus to the tumor directly, intrathecally or intravenously to cause tumor necrosis. The method of the present invention is particularly useful for the treatment of malignant tumors in various organs, such as: breast, colon, bronchial passage, epithelial lining of the gastrointestinal, upper respiratory and genito-urinary tracts, liver, prostate and the brain. Astounding remissions in experimental animals have been demonstrated for the treatment of malignant glioblastoma multiforme, an almost universally fatal neoplasm of the central nervous system.
Owner:NEW YORK UNIV OF RES FOUND OF THE
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
InactiveUS7226730B1Improve dementiaMicrobiological testing/measurementDisease diagnosisGerm layerMalignant astrocytoma
Disclosed are transgenic animals and transfected cell lines expressing a protein associated with Alzheimer's Disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. Also disclosed is the use of such transgenic animals and transfected cell lines to screen potential drug candidates for treating or preventing Alzheimer's disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. The invention also relates to new antisense oligonucleotides, ribozymes, triplex forming DNA and external guide sequences that can be used to treat or prevent Alzheimer's disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas.
Owner:THE GENERAL HOSPITAL CORP
Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE +1
Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
InactiveUS20080118512A1Less immunogenicTherapy is also rapidBacteriaSugar derivativesGlioblastomaTopical treatment
The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.
Owner:CELL MEDICA SWITZERLAND AG
Gene sets for glioma classification
The present invention provides a number of gene markers whose expression is altered in various gliomas. In particular, by examining the expression these markers, one can accurately classify a glioma as glioblastoma multiforme (GM), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO) or oligodendroglioma (OL). The diagnosis may be performed on nucleic acids, for example, using a DNA microarray, or on protein, for example, using immunologic means. Also disclosed are methods of therapy.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
Use of dianhydrogalactitol and analogs and derivatives thereof to treat glioblastoma multiforme
ActiveUS20140221442A1Improve survivalFree of side effectBiocideNervous disorderDianhydrogalactitolGlioblastoma
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
Owner:DEL MAR PHARMA
Multimodal nuclear magnetic resonance image segmentation method for glioblastoma
ActiveCN108447063ALow costImprove Segmentation AccuracyImage enhancementImage analysisNMR - Nuclear magnetic resonanceGlioblastoma
The invention provides a multimodal nuclear magnetic resonance image segmentation method for glioblastoma. The segmentation strategy combining the random forest method and the regional growth method is employed, the result of regional growth segmentation of a glioma multimodal magnetic resonance image is replaced with the corresponding random forest segmentation result with low confidence, retraining data is generated to re-train a random forest model, fine segmentation of the glioma multimodal magnetic resonance image is carried out, and a brain MRI image is segmented into a normal brain tissue area, a necrotic area, an active tumor area, a T1 abnormal area and a FLAIR abnormal area. The method is advantaged in that through fine segmentation and positioning of the glioblastoma, doctors are assisted in diagnosis and other treatment tasks, accurate positioning of the glioblastoma and more accurate fine segmentation of different tumor sub areas are carried out, the doctors are facilitated to diagnose the glioblastoma more quickly and accurately, and an accurate treatment scheme is made.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY
Novel method of diagnosing and treating gliomas
InactiveUS20050142062A1In-vivo radioactive preparationsPeptide/protein ingredientsGlioblastomaMonoclonal antibody
The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas.
Owner:SONTHEIMER HARALD W +1
Biomarkers and methods for the prognosis of glioblastoma
InactiveUS20140011702A1Improve conventional MGMT stratificationPromote stratificationMicrobiological testing/measurementLibrary screeningGlioblastomaTreatment response
The present invention relates to gene promoters whose methylation status correlates with the clinical survival outcome of glioblastoma patients treated according to the Stupp protocol. More specifically, the invention provides methods and kits for the prognosis of survival outcome and / or treatment response in glioblastoma patients.
Owner:CENT HOSPITALER UNIV PONTCHAILLOU
Nitrogen-containing aromatic heterocyclic compound
Provided is a compound useful as a prophylactic and / or therapeutic agent for bladder cancer.As a result of studies on compounds having FGFR inhibitory action, the present inventors have found that the nitrogen-containing aromatic heterocyclic compounds of the present invention have inhibitory action on FGFR1, FGFR2, and / or FGFR3, particularly, mutant FGFR3, and thus, the present invention has been accomplished. The nitrogen-containing aromatic heterocyclic compound of the present invention can be used as a therapeutic agent for various cancers related to FGFR1, FGFR2, and / or FGFR3, such as lung cancer and hormone therapy-resistant breast cancer, stomach cancer, triple negative breast cancer, endometrial cancer, bladder cancer, and glioblastoma, particularly as a prophylactic and / or therapeutic agent for mutant FGFR3-positive bladder cancer.
Owner:ASTELLAS PHARMA INC +1
Viral vectors for gene therapy
Adenovirus types 11p and 4p show a higher binding affinity and infectivity than type 5 for endothelial and carcinoma cell lines. Adenovirus type 11p shows a stronger binding to cells for neural origin, such as glioblastoma, neuroblastoma and medulloblastoma. The fact that adenovirus type 11 has a comparatively low prevalence in society, together with its high affinity and infectivity, makes it very suitable for use in gene therapy.
Owner:WADELL GORAN +4
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com